Siglec-2/CD22 Antibody (NCI m971) [DyLight 755] - (Research Grade Biosimilar)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28020IR
Recombinant Monoclonal Antibody

Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # NCI m971 expressed in CHO
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Siglec-2 / CD22
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Description
The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Patent #: US20110020344
Patent #: US20110020344
Applications
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Siglec-2/CD22
Long Name
Sialic Acid Binding Ig-like Lectin 2
Alternate Names
BL-CAM, CD22, Siglec2
Gene Symbol
CD22
Additional Siglec-2/CD22 Products
Product Specific Notices
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...